Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer

Clinical Breast Cancer

Volumn 3, Issue 2, 2002, Pages 147-152

  Jones, Stephen E ^a,b   Clark, Gary ^c   Koleszar, Sherry ^a   Ethington, Gaby ^a   Mennel, Robert ^a,b   Paulson, Steven ^b   Brooks, Barry ^b   Kerr, Ronald ^b   Denham, Claude ^b   Savin, Michael ^b   Blum, Joanne ^a,b   Kirby, Robert ^b   Stone, Marvin ^a,b   Pippen, John ^b   George, Timothy ^b   Orr, Douglas ^b   Knox, Sally ^d   Grant, Michael ^d   Peters, George ^d   Savino, Daniel ^a   Rietz, Charles ^a   more..

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Estrogen receptor; Progesterone receptor; Tamoxifen; Thymidine phosphorylase

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; MASTECTOMY; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0036348366     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.019     Document Type: Article

References (30)

1. Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma
2. Cell kinetics as a prognostic marker in node-negative breast cancer
3. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens
4. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry
5. Prognostic factors and treatment decisions in axillary-node-negative breast cancer
6. Multi-parameter flow cytometric analysis with detection of the Ki67-Ag in paraffin embedded mammary carcinomas
7. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas
8. Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: A prospective evaluation of 669 patients
9. Combination chemotherapy with Adriamycin and cyclophosphamide for advanced breast cancer
10. Adjuvant use of Adriamycin and cyclophosphamide in node negative carcinoma of the breast
11. Nonparametic estimation from incomplete observations
12. Regression models and life-tables
13. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors
14. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study
15. Evolving concepts in the systemic adjuvant treatment of breast cancer
16. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: Ten-year analysis--an intergroup study
17. Chemotherapy with or without tamoxifen for patients with ER negative breast cancer and negative nodes: Results from NSABP B23
18. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
19. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
20. Indicators of prognosis in node-negative breast cancer
21. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients
22. Cell proliferation in 3,800 node-negative breast cancers: Consistency over time of biological and clinical information provided by 3H-thymidine labelling index
23. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer
24. S-phase fraction and breast cancer--a decade of experience
25. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer
26. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer
27. Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients
28. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer
29. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer
30. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23